ArticleWorld journal of surgical oncology2026
miR-3648 regulates cell functions and acts as a potential biomarker to predict prognosis in breast cancer and its bioinformatics analysis.
Article in World journal of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer is an important cause of death from malignant tumors in women. This study aims to clarify the regulatory role, molecular mechanism and clinical value of miR-3648 in breast cancer.
methodsThis study analyzed 126 pairs of clinical samples of breast cancer. The expression of miR-3648 and its potential target SMAD6 was detected by qRT-PCR. Survival outcomes were assessed by Kaplan-Meier analysis and Cox regression model. In the MCF-7 and BT-474 cell lines, function gain and loss experiments were conducted using miR-3648 mimic or inhibitor. Biological behaviors modulated by miR-3648, including cell proliferation, migration and invasion were assessed using CCK-8 and Transwell assays. The target genes of miR-3648 were predicted by bioinformatics, and their relationship was verified by dual-luciferase.
resultsMiR-3648 was significantly upregulated in breast cancer and correlated with unfavorable clinicopathological features and predicted the survival rate of patients. In vitro experiments revealed that overexpression of miR-3648 promotes the proliferation, migration, and invasion of breast cancer cells, while inhibition of its expression yields opposite effects. Bioinformatics analysis and verification experiments jointly identified SMAD6 as the functional target of miR-3648. SMAD6 and miR-3648 expression was inversely correlated in breast cancer tissues, and SMAD6 knockdown partially reversed the effects of miR-3648 inhibition.
conclusionsmiR-3648 exerts its role in promoting the progression of breast cancer by directly targeting and inhibiting SMAD6, and can serve as a potential biomarker for evaluating the prognosis of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.